Literature DB >> 2920737

The behavior of 99mTc-hexamethylpropyleneamineoxime (99mTc-HMPAO) in blood and brain.

K Nakamura1, Y Tukatani, A Kubo, S Hashimoto, Y Terayama, T Amano, F Goto.   

Abstract

99mTc-hexamethylpropyleneamineoxime (99mTc-HMPAO) is a reagent for scanning cerebral blood flow. We investigated how 99mTc-HMPAO changed in the blood and brain. The 99mTc-HMPAO, which was prepared by adding of 99mTcO4- to HMPAO and Sn(II), consisted of primary and secondary complexes, reduced hydrolyzed 99mTc, and 99mTc-pertechnetate. The percentage of the primary complex in 99mTc-HMPAO decreased with time after preparation. The primary complex converted to the secondary one very rapidly in the presence of plasma. When 99mTc-HMPAO was injected into patients, 99mTc activity was immediately partitioned in the plasma fraction, with approximately 60% in whole blood. In plasma, 99mTc was found to be associated with proteins such as albumin and globulin. 99mTc trapped in red cells was not washed out with either plasma or saline. Biodistribution studies showed that the less lipophilic compounds of 99mTc-HMPAO could not pass through the blood brain barrier (BBB), and therefore did not accumulate in the brain. The results of gel chromatography and equilibrium dialysis indicated that no specific 99mTc binding protein was present in the brain. Considering the instability of 99mTc-HMPAO in vivo, we proposed that the speed at which the primary complex converted to the less lipophilic compounds was important in allowing 99mTc-HMPAO to pass through the BBB and to be fixed in the brain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920737     DOI: 10.1007/BF00702628

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

1.  The in vivo distribution of 99Tcm-HM-PAO in normal man.

Authors:  D C Costa; P J Ell; I D Cullum; P H Jarritt
Journal:  Nucl Med Commun       Date:  1986-09       Impact factor: 1.690

2.  99mTc-HMPAO as a tumour blood flow agent.

Authors:  P A Hammersley; V R McCready; J W Babich; G Coghlan
Journal:  Eur J Nucl Med       Date:  1987

3.  Initial experience with SPECT (single-photon computerized tomography) of the brain using N-isopropyl I-123 p-iodoamphetamine: concise communication.

Authors:  T C Hill; B L Holman; R Lovett; D H O'Leary; D Front; P Magistretti; R E Zimmerman; S Moore; M E Clouse; J L Wu; T H Lin; R M Baldwin
Journal:  J Nucl Med       Date:  1982-03       Impact factor: 10.057

4.  Brain SPECT imaging with 99Tcm-hexamethylpropyleneamine oxime in the early detection of cerebral infarction: comparison with transmission computed tomography.

Authors:  S H Yeh; R S Liu; H H Hu; W J Wong; Y K Lo; Z Y Lai; J C Huang; S L Chang; S J Wang; F L Chu
Journal:  Nucl Med Commun       Date:  1986-12       Impact factor: 1.690

5.  Initial experience with SPECT of the brain using 99mTc-hexamethyl-propyleneamine oxime (99mTc-HM-PAO).

Authors:  G Spreafico; F Cammelli; G Gadola; G Nicola; F Zancaner; G Tonnarelli; E Sala; R Freschi
Journal:  Eur J Nucl Med       Date:  1987

6.  Initial experience with technetium-99m HM-PAO brain SPECT.

Authors:  I Podreka; E Suess; G Goldenberg; M Steiner; T Brücke; C Müller; W Lang; R D Neirinckx; L Deecke
Journal:  J Nucl Med       Date:  1987-11       Impact factor: 10.057

7.  Differential diagnosis in dementia using the cerebral blood flow agent 99mTc HM-PAO: a SPECT study.

Authors:  H G Gemmell; P F Sharp; J A Besson; J R Crawford; K P Ebmeier; J Davidson; F W Smith
Journal:  J Comput Assist Tomogr       Date:  1987 May-Jun       Impact factor: 1.826

8.  Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion.

Authors:  R D Neirinckx; L R Canning; I M Piper; D P Nowotnik; R D Pickett; R A Holmes; W A Volkert; A M Forster; P S Weisner; J A Marriott
Journal:  J Nucl Med       Date:  1987-02       Impact factor: 10.057

9.  Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies.

Authors:  P F Sharp; F W Smith; H G Gemmell; D Lyall; N T Evans; D Gvozdanovic; J Davidson; D A Tyrrell; R D Pickett; R D Neirinckx
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

10.  99mTc-propylene amine oxime (99mTc-PnAO); a potential brain radiopharmaceutical.

Authors:  W A Volkert; T J Hoffman; R M Seger; D E Troutner; R A Holmes
Journal:  Eur J Nucl Med       Date:  1984
  10 in total
  8 in total

1.  Evaluation of technetium 99m cyclobutylpropylene amine oxime as a potential brain perfusion imaging agent for SPET.

Authors:  L Bacciottini; F Lunghi; A Pupi; C Bonino; A R Formiconi; M T De Cristofaro; A R Petti; U Meldolesi
Journal:  Eur J Nucl Med       Date:  1990

2.  Radiochemical purity of D,L-hexamethylpropylene amine oxime and analysis of urine-excreted HMPAO decomposition species.

Authors:  V Ivancević; Z Kuster; Z Mastrović; D Ivancević
Journal:  Eur J Nucl Med       Date:  1990

3.  Evaluation of primary lung carcinoma using technetium 99m-hexamethylpropylene amine oxime: preliminary clinical experience.

Authors:  M Oshima; K Itoh; S Okae; M Tadokoro; Y Kodama; S Sakuma
Journal:  Eur J Nucl Med       Date:  1990

4.  Quantification of technetium-99m hexamethylpropylene amine oxime brain uptake in routine clinical practice using calibrated point sources as an external standard: phantom and human studies.

Authors:  A Dobbeleir; R Dierckx
Journal:  Eur J Nucl Med       Date:  1993-08

5.  Parameters influencing SPET regional brain uptake of technetium-99m hexamethylpropylene amine oxine measured by calibrated point sources as an external standard.

Authors:  R A Dierckx; A Dobbeleir; M Maes; B A Pickut; A Vervaet; P P De Deyn
Journal:  Eur J Nucl Med       Date:  1994-06

6.  Influence of hyperthermia on carotid blood flow using 99mTc-HMPAO.

Authors:  Seham Mustafa; Abdelhamid H Elgazzar; Hishaam N Ismael
Journal:  Eur J Appl Physiol       Date:  2007-07-12       Impact factor: 3.078

Review 7.  Brain perfusion single photon emission computed tomography in major psychiatric disorders: From basics to clinical practice.

Authors:  Amburanjan Santra; Rakesh Kumar
Journal:  Indian J Nucl Med       Date:  2014-10

8.  [18F]CB251 PET/MR imaging probe targeting translocator protein (TSPO) independent of its Polymorphism in a Neuroinflammation Model.

Authors:  Kyungmin Kim; Ha Kim; Sung-Hwan Bae; Seok-Yong Lee; Young-Hwa Kim; Juri Na; Chul-Hee Lee; Min Sun Lee; Guen Bae Ko; Kyeong Yun Kim; Sang-Hee Lee; In Ho Song; Gi Jeong Cheon; Keon Wook Kang; Sang Eun Kim; June-Key Chung; Euishin Edmund Kim; Sun-Ha Paek; Jae Sung Lee; Byung Chul Lee; Hyewon Youn
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.